| Name | Title | Contact Details |
|---|
Bexion Pharmaceuticals is a Cincinnati, OH-based company in the Business Services sector.
T3 New York is a New York, NY-based company in the Business Services sector.
MARA is a company focused on sustainable energy solutions, utilizing digital technologies to drive energy transformation. The company specializes in converting clean, stranded, or underutilized energy into economic value, playing a vital role in the energy sector. MARA offers several key services, including energy harvesting, which transforms unconventional energy sources like landfill waste and flared gas into usable electricity. This electricity powers modular data centers, with the heat generated being recycled for industrial applications. Additionally, MARA deploys utility-scale computing through large, flexible data centers that utilize excess power generation, enhancing the economic viability of energy projects. The company also provides a Technology Suite that includes advanced cooling technology and custom firmware to improve Bitcoin mining efficiency. MARAs services target sectors that require energy solutions and are involved in the cryptocurrency ecosystem, contributing to the advancement of energy and microgrid technologies.
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN
Enova Engineering Services is a Walnut Creek, CA-based company in the Business Services sector.